PROTEOMIC URINE EXAMINATION OF PATIENTS WITH GLOMERULONEPHROPATHY AND RENAL CANCER

AIM. Search of noninvasive methods of diagnostics of chronic glomerulonephritis (CGN) emergence and progression based on outcome analyses of standard methods and proteomic urine examination. PATIENTS AND METHODS. The study included 60 patients which were divided into two groups. First group included 30 patients with renal cancer (RC). Average age 52,8±2,6 years. Morphologic variants of renal cancer were presented by three forms: clear-cell carcinoma (n=15), papillary carcinoma (n=9) and chromophobe carcinoma (n=6). Second group included 30 patients with CGN (18 male and 12 female), average age 37,2±1,3 years. According to results of nephrobiopsy in group of patients with CGN were revealed following morphologic variants: IgA-nephropathy (n=12); membranous proliferative glomerulonephritis (MPGN, n=7), focal segmental glomerulosclerosis (FSGS, n=5), minimal change disease (lipoid nephrosis) (LN, n=4), membranous glomerulonephritis (MGN, n=2). Control group was formed from practically healthy people, average age 52,1±1,8 years. To all patients were carried out general research methods (kidneys ultrasound, general blood analysis, general urine analysis, creatinine and blood urea concentration) and mass spectrometry of urine. RESULTS. Were revealed clinical and laboratory signs of CGN: arterial hypertension, anemy, azotemia, hypoproteinemia, hypoalbuminemia, hypercholesterinemia, hypercoagulation, hyperhidratation, proteinuria, micro- and macrohematuria, lymphocyteuria, cylindruria, decrease of glomerular filtration rate. Were revealed functional groups of new proteins which composed molecular profiles of patients with CGN explaining mechanisms of anemia progression, immune-inflammatory process, hypoxia and angiogenesis in renal parenchyma. CONCLUSION. Analysis of proteomic urine spectrum of patients with CGN and RC provides to divide protein spectrum into conditional groups. It provides to identify received proteins as potential sensitive and specific markers of disease emergence and progression.

1. Батюшин ММ. Клиническая нефрология. ЗАО НПП «Джангар», Элиста, 2009; 656

2. Мухин НА. Диагностика и лечение болезней почек. М.: ГЭОТАР-Медиа, 2011; 383

3. Нефрология: национальное руководство. ГЭОТАРМедиа, М., 2009; 716

4. Шилов ЕМ. Нефрология. ГЭОТАР-Медиа, М., 2010; 696

5. Официальный сайт Федеральной службы государственной статистики РФ, доступен на http://www.gks.ru (1 декабря 2011).

6. Паскалев Д, Танчева С. Клинико-лабораторные признаки, способствующие объективизации диагностики обострения хронического пиелонефрита. Нефрология 2007; (1): 5

7. Сарвилина ИВ. Междисциплинарные исследования в медицине (Мир биологии и медицины). Техносфера, М., 2007; 368

8. Рич Дж.П. Онкоурология. Бином, М., 2011; 896

9. Томилина НА, Бикбов БТ. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболеваний почек. Тер арх 2005; 77(6):87-92

10. Banks R, Dunn M, Hochstrasser D. Proteomics: New perspectives, new biomedical opportunities. Lancet 2000; 356:1749–1756

11. Bowling CB, Muntner P. Epidemiology of Chronic Kidney Disease Among Older Adults: A Focus on the Oldest Old. J Gerontol A Biol Sci Med Sci 2012; Sep 7 [Epub ahead of print] PubMed PMID: 22960475

12. Caiazzo RJJr, Maher AJ, Drummond MP, Lander CI, Tassinari OW, Nelson BP, Liu BCS. Protein microarrays as an application for disease biomarkers. Proteomics Clin Appl 3(2):138-147. [doi:10.1002/prca. 200800149]

13. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011 Oct;80(8):806-21. doi: 10.1038/ ki.2011.198. Epub 2011 Jun 22. Review. PubMed PMID: 21697815.